Chicago Capital LLC Sells 98,406 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Chicago Capital LLC lessened its position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 1.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,693,329 shares of the biopharmaceutical company's stock after selling 98,406 shares during the quarter. Dynavax Technologies makes up 2.9% of Chicago Capital LLC's investment portfolio, making the stock its 10th largest holding. Chicago Capital LLC owned approximately 4.40% of Dynavax Technologies worth $79,593,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of DVAX. Advisors Asset Management Inc. increased its holdings in shares of Dynavax Technologies by 498.0% in the 1st quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 1,967 shares during the last quarter. Quantbot Technologies LP raised its position in shares of Dynavax Technologies by 940.7% during the 1st quarter. Quantbot Technologies LP now owns 2,508 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 2,267 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth about $33,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth about $33,000. Finally, Bartlett & CO. Wealth Management LLC acquired a new stake in shares of Dynavax Technologies during the 4th quarter worth about $50,000. Hedge funds and other institutional investors own 96.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Wednesday, March 6th. The Goldman Sachs Group assumed coverage on Dynavax Technologies in a research note on Thursday, February 1st. They set a "neutral" rating and a $20.00 price target on the stock. Finally, William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $25.00.

Dynavax Technologies Price Performance

DVAX stock traded down $0.27 during midday trading on Tuesday, hitting $12.31. 2,400,468 shares of the stock were exchanged, compared to its average volume of 2,006,504. The stock's 50-day moving average price is $12.66 and its 200-day moving average price is $13.49. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -205.13 and a beta of 1.26. Dynavax Technologies Co. has a fifty-two week low of $9.73 and a fifty-two week high of $15.15. The company has a debt-to-equity ratio of 0.41, a quick ratio of 12.96 and a current ratio of 13.81.

Insider Transactions at Dynavax Technologies

In other news, CAO Justin Burgess sold 20,526 shares of the business's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $12.78, for a total value of $262,322.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.31% of the company's stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.